ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma

Genes and Cancer

Volumn 4, Issue 11-12, 2013, Pages 486-500

  Wiles, Elizabeth T ^a,b   Bell, Russell ^a,c   Thomas, Dafydd ^d   Beckerle, Mary ^a,b,c   Lessnick, Stephen L ^a,b,c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

EMT; Ewing sarcoma; EWS FLI; metastasis; ZEB2

Indexed keywords

NUCLEIC ACID BINDING PROTEIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; CYTOSKELETON; EPITHELIUM CELL; EWING SARCOMA; GENE CONSTRUCT; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; TISSUE MICROARRAY; TISSUE PREPARATION; WESTERN BLOTTING;

EID: 84891542120     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601913506115     Document Type: Article

References (76)

1. Gupta GP,Massague J.Cancer metastasis: building a framework.Cell. 2006;127:679-95.
2. Fidler IJ.The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited.Nat Rev Cancer. 2003;3:453-8.
3. Tsai JH,Donaher JL,Murphy DA,Chau S,Yang J.Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis.Cancer Cell. 2012;22:725-36.
4. Ocana OH,Corcoles R,Fabra A, et al.Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1.Cancer Cell. 2012;22:709-24.
5. Brabletz T,Jung A,Reu S, et al.Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A. 2001;98:10356-61.
6. Thiery JP.Epithelial-mesenchymal transitions in tumour progression.Nat Rev Cancer. 2002;2:442-54.
7. Helman LJ,Meltzer P.Mechanisms of sarcoma development.Nat Rev Cancer. 2003;3:685-94.
8. Taylor BS,Barretina J,Maki RG,Antonescu CR,Singer S,Ladanyi M.Advances in sarcoma genomics and new therapeutic targets.Nat Rev Cancer. 2011;11:541-57.
9. Fitzgerald MP,Gourronc F,Teoh ML, et al.Human chondrosarcoma cells acquire an epithelial-like gene expression pattern via an epigenetic switch: evidence for mesenchymal-epithelial transition during sarcomagenesis.Sarcoma. 2011;2011:598218.
10. Guo Y,Zi X,Koontz Z, et al.Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells.J Orthop Res. 2007;25:964-71.
11. Yang J,Eddy JA,Pan Y, et al.Integrated proteomics and genomics analysis reveals a novel mesenchymal to epithelial reverting transition in leiomyosarcoma through regulation of slug.Mol Cell Proteomics. 2010;9:2405-13.
12. Niinaka Y,Harada K,Fujimuro M, et al.Silencing of autocrine motility factor induces mesenchymal-to-epithelial transition and suppression of osteosarcoma pulmonary metastasis.Cancer Res. 2010;70:9483-93.
13. Arndt CA,Crist WM.Common musculoskeletal tumors of childhood and adolescence.N Engl J Med. 1999;341:342-52.
14. von Levetzow C,Jiang X,Gwye Y, et al.Modeling initiation of Ewing sarcoma in human neural crest cells.PLoS One. 2011;6:e19305.
15. Miyagawa Y,Okita H,Nakaijima H, et al.Inducible expression of chimeric EWS/ETS proteins confers Ewing's family tumor-like phenotypes to human mesenchymal progenitor cells.Mol Cell Biol. 2008;28:2125-37.
16. Riggi N,Suva ML,Suva D, et al.EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.Cancer Res. 2008;68:2176-85.
17. Riggi N,Suva ML,Stamenkovic I.Ewing's sarcoma origin: from duel to duality.Expert Rev Anticancer Ther. 2009;9:1025-30.
18. Lee G,Kim H,Elkabetz Y, et al.Isolation and directed differentiation of neural crest stem cells derived from human embryonic stem cells.Nat Biotechnol. 2007;25:1468-75.
19. Takashima Y,Era T,Nakao K, et al.Neuroepithelial cells supply an initial transient wave of MSC differentiation.Cell. 2007;129:1377-88.
20. Wang CC,Schulz MD.Ewing's sarcoma: a study of fifty cases treated at the Massachusetts General Hospital, 1930-1952 inclusive.N Engl J Med. 1953;248:571-6.
21. Dahlin DC,Coventry MB,Scanlon PW.Ewing's sarcoma. A critical analysis of 165 cases.J Bone Joint Surg Am. 1961;43:185-92.
22. Grier HE,Krailo MD,Tarbell NJ, et al.Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.N Engl J Med. 2003;348:694-701.
23. Acloque H,Adams MS,Fishwick K,Bronner-Fraser M,Nieto MA.Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease.J Clin Invest. 2009;119:1438-49.
24. Chaturvedi A,Hoffman LM,Welm AL,Lessnick SL,Beckerle MC.The EWS/FLI oncogene drives changes in cellular morphology, adhesion, and migration in Ewing sarcoma.Genes Cancer. 2012;3:102-16.
25. Tirode F,Laud-Duval K,Prieur A,Delorme B,Charbord P,Delattre O.Mesenchymal stem cell features of Ewing tumors.Cancer Cell. 2007;11:421-9.
26. Gu M,Antonescu CR,Guiter G,Huvos AG,Ladanyi M,Zakowski MF.Cytokeratin immunoreactivity in Ewing's sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies.Am J Surg Pathol. 2000;24:410-6.
27. Collini P,Sampietro G,Bertulli R, et al.Cytokeratin immunoreactivity in 41 cases of ES/PNET confirmed by molecular diagnostic studies.Am J Surg Pathol. 2001;25:273-4.
28. Schuetz AN,Rubin BP,Goldblum JR, et al.Intercellular junctions in Ewing sarcoma/primitive neuroectodermal tumor: additional evidence of epithelial differentiation.Mod Pathol. 2005;18:1403-10.
29. Baird K,Davis S,Antonescu CR, et al.Gene expression profiling of human sarcomas: insights into sarcoma biology.Cancer Res. 2005;65:9226-35.
30. Kalluri R,Weinberg RA.The basics of epithelial-mesenchymal transition.J Clin Invest. 2009;119:1420-28.
31. Yang J,Weinberg RA.Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis.Dev Cell. 2008;14:818-29.
32. Comijn J,Berx G,Vermassen P, et al.The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion.Mol Cell. 2001;7:1267-78.
33. Kovar H.Context matters: the hen or egg problem in Ewing's sarcoma.Semin Cancer Biol. 2005;15:189-96.
34. Ramaswamy S,Ross KN,Lander ES,Golub TR.A molecular signature of metastasis in primary solid tumors.Nat Genet. 2003;33:49-54.
35. Sainz-Jaspeado M,Lagares-Tena L,Lasheras J, et al.Caveolin-1 modulates the ability of Ewing's sarcoma to metastasize.Mol Cancer Res. 2010;8:1489-500.
36. Huang da W,Sherman BT,Lempicki RA.Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.Nucleic Acids Res. 2009;37:1-13.
37. Huang da W,Sherman BT,Lempicki RA.Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.Nat Protoc. 2009;4:44-57.
38. Machado I,Lopez-Guerrero JA,Navarro S, et al.Epithelial cell adhesion molecules and epithelial mesenchymal transition (EMT) markers in Ewing's sarcoma family of tumors (ESFTs). Do they offer any prognostic significance? Virchows Arch. 2012;461:333-7.
39. Taube JH,Herschkowitz JI,Komurov K, et al.Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes.Proc Natl Acad Sci U S A. 2010;107:15449-54.
40. Gautier L,Cope L,Bolstad BM,Irizarry RA.affy-analysis of Affymetrix GeneChip data at the probe level.Bioinformatics. 2004;20:307-15.
41. Onder TT,Gupta PB,Mani SA,Yang J,Lander ES,Weinberg RA.Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways.Cancer Res. 2008;11:3645-54.
42. Keshamouni VG,Jagtap P,Michailidis G, et al.Temporal quantitative proteomics by iTRAQ 2D-LC-MS/MS and corresponding mRNA expression analysis identify post-transcriptional modulation of actin-cytoskeleton regulators during TGF-beta-Induced epithelial-mesenchymal transition.J Proteome Res. 2009;8:35-47.
43. Sartor MA,Mahavisno V,Keshamouni VG, et al.ConceptGen: a gene set enrichment and gene set relation mapping tool.Bioinformatics. 2010;26:456-63.
44. Keshamouni VG,Michailidis G,Grasso CS, et al.Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype.J Proteome Res. 2006;5:1143-54.
45. Park SM,Gaur AB,Lengyel E,Peter ME.The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.Genes Dev. 2008;22:894-907.
46. Postigo AA,Dean DC.Differential expression and function of members of the zfh-1 family of zinc finger/homeodomain repressors.Proc Natl Acad Sci U S A. 2000;97:6391-6.
47. Gregory PA,Bert AG,Paterson EL, et al.The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.Nat Cell Biol. 2008;10:593-601.
48. Brabletz S,Brabletz T.The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer?.EMBO Rep. 2010;11:670-7.
49. Guan H,Zhou Z,Gallick GE, et al.Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma.Mol Cancer Ther. 2008;7:1807-16.
50. Dolled-Filhart M,Gustavson M,Camp RL,Rimm DL,Tonkinson JL,Christiansen J.Automated analysis of tissue microarrays.Methods Mol Biol. 2010;664:151-62.
51. Spraker HL,Price SL,Chaturvedi A, et al.The clone wars-revenge of the metastatic rogue state: the sarcoma paradigm.Front Oncol. 2012;2:2.
52. Klein CA.Parallel progression of primary tumours and metastases.Nat Rev Cancer. 2009;9:302-12.
53. Fearon ER,Vogelstein B.A genetic model for colorectal tumorigenesis.Cell. 1990;61:759-67.
54. Stahl M,Ranft A,Paulussen M, et al.Risk of recurrence and survival after relapse in patients with Ewing sarcoma.Pediatr Blood Cancer. 2011;57:549-53.
55. Muller V,Stahmann N,Riethdorf S, et al.Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity.Clin Cancer Res. 2005;11:3678-85.
56. Chambers AF,Groom AC,MacDonald IC.Dissemination and growth of cancer cells in metastatic sites.Nat Rev Cancer. 2002;2:563-572.
57. Pantel K,Brakenhoff RH,Brandt B.Detection, clinical relevance and specific biological properties of disseminating tumour cells.Nat Rev Cancer. 2008;8:329-40.
58. Meng S,Tripathy D,Frenkel EP, et al.Circulating tumor cells in patients with breast cancer dormancy.Clin Cancer Res. 2004;10:8152-62.
59. Brabletz T.To differentiate or not-routes towards metastasis.Nat Rev Cancer. 2012;12:425-36.
60. Shukla N,Ameur N,Yilmaz I, et al.Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.Clin Cancer Res. 2012;18:748-57.
61. Huang HY,Illei PB,Zhao Z, et al.Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse.J Clin Oncol. 2005;23:548-58.
62. Van de Putte T,Maruhashi M,Francis A, et al.Mice lacking ZFHX1B, the gene that codes for Smad-interacting protein-1, reveal a role for multiple neural crest cell defects in the etiology of Hirschsprung disease-mental retardation syndrome.Am J Hum Genet. 2003;72:465-70.
63. Torchia EC,Jaishankar S,Baker SJ.Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells.Cancer Res. 2003;63:3464-8.
64. Riggi N,Suva ML,De Vito C, et al.EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells.Genes Dev. 2010;24:916-32.
65. Gallicano GI,Bauer C,Fuchs E.Rescuing desmoplakin function in extra-embryonic ectoderm reveals the importance of this protein in embryonic heart, neuroepithelium, skin and vasculature.Development. 2001;128:929-41.
66. Dellagi K,Lipinski M,Paulin D,Portier MM,Lenoir GM,Brouet JC.Characterization of intermediate filaments expressed by Ewing tumor cell lines.Cancer Res. 1987;47:1170-3.
67. Jackson BW,Grund C,Winter S,Franke WW,Illmensee K.Formation of cytoskeletal elements during mouse embryogenesis. II. Epithelial differentiation and intermediate-sized filaments in early postimplantation embryos.Differentiation. 1981;20:203-16.
68. Viebahn C,Lane EB,Ramaekers FC.Cytoskeleton gradients in three dimensions during neurulation in the rabbit.J Comp Neurol. 1995;363:235-48.
69. Codrington R,Pannell R,Forster A, et al.The Ews-ERG fusion protein can initiate neoplasia from lineage-committed haematopoietic cells.PLoS Biol. 2005;3:e242.
70. Torchia EC,Boyd K,Rehg JE,Qu C,Baker SJ.EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice.Mol Cell Biol. 2007;27:7918-34.
71. Lin PP,Pandey MK,Jin F, et al.EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model.Cancer Res. 2008;68:8968-75.
72. Wiles ET,Lui-Sargent B,Bell R,Lessnick SL.BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma.PLoS One. 2013;8:e59369.
73. Smith R,Owen LA,Trem DJ, et al.Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma.Cancer Cell. 2006;9:405-16.
74. Masutomi K,Yu EY,Khurts S, et al.Telomerase maintains telomere structure in normal human cells.Cell. 2003;114:241-53.
75. Wettenhall JM,Smyth GK.limmaGUI: a graphical user interface for linear modeling of microarray data.Bioinformatics. 2004;20:3705-6.
76. Luo W,Milash B,Dalley B, et al.Antibody detection of translocations in Ewing sarcoma.EMBO Mol. Med. 2012;4:453-61.